Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?

Clinical Endocrinology

Volumn 67, Issue 2, 2007, Pages 310-315

  Jallad, Raquel S ^a   Musolino, Nina R ^a   Kodaira, Sergio ^a   Cescato, Valter A ^a   Bronstein, Marcello D ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ACROMEGALY; ADENOMA; ADULT; AGED; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE CONTROL; FEMALE; GROWTH HORMONE BLOOD LEVEL; HORMONE BLOOD LEVEL; HUMAN; HYPOPHYSIS TUMOR; MACROADENOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SELLA TURCICA; SLOW DRUG RELEASE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; GROWTH HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OCTREOTIDE; PITUITARY NEOPLASMS; PROSPECTIVE STUDIES; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 34447523623     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02885.x     Document Type: Article

References (18)

1. Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Wass, J., Von Werder, K. Melmed, S. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526 529.
2. De, P., Rees, D.A., Davies, N., John, R., Neal, J., Mills, R.G., Vafidis, J., Davies, J.S. Scanlon, M.F. (2003) Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. Journal of Clinical Endocrinology and Metabolism, 88, 3567 3572.
3. Nomikos, P., Buchfelder, M. Fahlbusch, R. (2005) The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. European Journal of Endocrinology, 152, 379 387.
4. Beauregard, C., Truong, U., Hardy, J. Serri, O. (2003) Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly. Clinical Endocrinology, 58, 86 91.
5. Shimon, I., Cohen, Z.R., Ram, Z. Hadani, M. (2001) Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery, 48, 1239 1243.
6. Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S. Rabinowitz, D. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465 4473.
7. Colao, A., Ferone, D., Marzullo, P., Cappabianca, P., Cirillo, S., Boerlin, V., Lancranjan, I. Lombardi, G. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 2779 2786.
8. Bevan, J.S., Atkin, S.L., Atkinson, A.B., Bouloux, P.M., Hanna, F., Harris, P.E., James, R.A., McConnell, M., Roberts, G.A., Scanlon, M.F., Stewart, P.M., Teasdale, E., Turner, H.E., Wass, J.A.H. Wardlaw, J.M. (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism, 87, 4554 4563.
9. Ayuk, J., Stewart, S.E., Stewart, P.M. Sheppard, M.C. (2004) Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clinical Endocrinology, 60, 375 381.
10. Jallad, R.S., Musolino, N.R., Salgado, L.R. Bronstein, M.D. (2005) Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clinical Endocrinology, 63, 168 175.
11. Petrossians, P., Martins, L.B., Espinoza, C., Daly, A., Betea, D., Valdes-Socin, H., Stevenaert, A., Chanson, P. Beckers, A. (2005) Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. European Journal of Endocrinology, 152, 1 7.
12. Colao, A., Attanasio, R., Pivonello, R., Cappabianca, P., Cavallo, L.M., Lasio, G., Lodrini, A., Lombardi, G. Cozzi, R. (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 91, 85 92.
13. Wass, J.A.H., Fazal-Sanderson, V., Byrne, J., Rowel, S., Karavitaki, N., Trainer, P. Turner, H.E. (2006) Surgical debulking of GH secreting adenomas improves control of acromegaly by lanreotide - a prospective study. Endocrine Abstracts Poster 548, 8th European Congress of Endocrinology incorporating the British Endocrine Societies.
14. Lundin, P. Pedersen, F. (1992) Volume of pituitary macroadenomas: assessment by MRI. Journal of Computer Assisted Tomography, 16, 518 528.
15. Neter, J., Kutner, M.H., Nachtsheim, C.J. Wasserman, W. (1996) Applied Linear Statistical Models, 4th edn. Irwin, Chicago.
16. Patel, Y.C. (1999) Somatostatin and its receptor family. Frontiers in Neuroendocrinology, 20, 157 198.
17. Jaquet, P., Saveanu, A., Gunz, G., Fina, F., Zamora, A.J., Grino, M., Culler, M.D., Moreau, J.P., Enjalbert, A. Ouafik, L.H. (2000) Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism, 85, 781 792.
18. Abosch, A., Tyrrell, J.B., Lamborn, K.R., Hannegan, L.T., Applebury, C.B. Wilson, C.B. (1998) Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism, 83, 3411 3418.